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Abstract
Background: Polymorphism of the Duffy Antigen Receptor for Chemokines (DARC) is associated with susceptibility to and
the severity of Plasmodium vivax malaria in humans. P. vivax uses DARC to invade erythrocytes. Individuals lacking DARC are
‘resistant’ to P. vivax erythrocytic infection. However, susceptibility to P. vivax in DARC+ individuals is reported to vary
between specific DARC genotypes. We hypothesized that the natural acquisition of antibodies to P. vivax blood stages may
vary with the host genotype and the level of DARC expression. Furthermore, high parasitemia has been reported to effect
the acquisition of immunity against pre-erythrocytic parasites. We investigated the correlation between host DARC
genotypes and the frequency and magnitude of antibodies against P. vivax erythrocytic stage antigens.
Methodology/Findings: We assessed the frequencies and magnitudes of antibody responses against P. vivax and P.
falciparum sporozoite and erythrocytic antigens in Colombian donors from malaria-endemic regions. The frequency and
level of naturally-acquired antibodies against the P. vivax erythrocytic antigens merozoite surface protein 1 (PvMSP1) and
Duffy binding protein (PvDBP) varied with the host DARC genotypes. Donors with one negative allele (FY*B/FY*Bnull and
FY*A/FY*Bnull) were more likely to have anti-PvMSP1 and anti-PvDBP antibodies than those with two positive alleles (FY*B/
FY*B and FY*A/FY*B). The lower IgG3 and IgG1 components of the total IgG response may account for the decreased
responses to P. vivax erythrocytic antigens with FY*A/FY*B and FY*B/FY*B genotypes. No such association was detected
with P. falciparum erythrocytic antigens, which does not use DARC for erythrocyte invasion.
Conclusion/Significance: Individuals with higher DARC expression, which is associated with higher susceptibility to P. vivax
infection, exhibited low frequencies and magnitudes of P. vivax blood-stage specific antibody responses. This may indicate
that one of the primary mechanisms by which P. vivax evades host immunity is through DARC indirectly down-regulating
humoral responses against erythrocytic invasion and development.
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Introduction
Malaria remains the most important parasitic infection in the
world with almost half a billion clinical cases every year [1]. It is
caused by infection with one or more of five species of Plasmodium
parasites. However, two species, P. falciparum and P. vivax, are
responsible for most of the morbidity and mortality due to malaria
[2,3,4,5,6]. P. vivax malaria does not attract as much attention
from the scientific community, government entities or funding
agencies as does the more deadly P. falciparum malaria. This is
partly because P. vivax malaria was in the past erroneously referred
to as ‘benign’ tertian malaria. But recent studies have revealed that
vivax malaria can potentially lead to severe debilitating compli-
cations and about 2 billion people spread across 3 continents are
continuously at risk of the infection [3,4,5,6,7,8]. The discovery
and development of novel interventions, most especially vaccines,
will depend upon a better understanding of parasite biology and
the naturally induced immune response in humans [9,10,11,12].
An important biological difference between P. vivax and P.
falciparum is that only P. vivax merozoites use the Duffy (Fy)
antigen/receptor for chemokines (DARC) to invade erythrocytes
[13,14]. DARC is a glycosylated membrane protein that is
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11437encoded by a gene located on the long arm of chromosome 1
[15,16,17,18,19]. DARC is more abundant on the surface of
reticulocytes than on mature erythrocytes and is also expressed on
the endothelial surfaces of some organs [17,18]. DARC binds to
most inflammatory chemokines and its roles in the immune system
include leukocyte activation and recruitment [20,21]. In addition,
DARC is associated with protection and susceptibility to a number
of other infectious and non-infectious diseases [22,23,24,25],
potentially via its elimination of excess toxic chemokines produced
during infectious processes and its regulation of leukocyte
trafficking [26,27]. Finally, DARC is the essential receptor
required for the entry of P. vivax into erythrocytes [13].
Genetic polymophisms have been identified in humans that
affect the expression of the Duffy antigen and the susceptibility to
blood stage infection by P. vivax.F y + individuals have 5 common
genotypes (FY*A/FY*A, FY*A/FY*B, FY*A/FY*Bnull, FY*B/
FY*B and FY*B/FY*Bnull) that produce 3 major phenotypes (Fy
a
+/b
+,F ya
+/b
2,F ya
2/b
+). Red cells from all Fy+ individuals are
susceptible to P. vivax infection. People with mutations in the
DARC promoter region that abolish DARC expression (FY*B-
null/FY*Bnull or FY*O) exhibit a Duffy-negative phenotype
(Fy2) [28,29,30]. Erythrocytes of Fy2 individuals cannot be
invaded by P. vivax merozoites such that Fy2 individuals are
refractory to P. vivax blood stage infection. However, since
sporozoite invasion of hepatocytes does not involve DARC, both
Fy+ and Fy2 individuals are susceptible to infection by
sporozoites and develop liver stage parasites. But upon release of
liver merozoites into the circulation, only Fy+ individuals develop
blood stage infections because the erythrocytes of Fy(2) individ-
uals do not express DARC required for erythrocyte invasion by
merozoites.
The requirement for DARC in erythrocytic vivax infection
limits the infection to the liver stage in Fy2 individuals. However,
both humoral and cellular immune responses against P. vivax pre-
erythrocytic parasites have been reported in Fy2 humans [31].
The frequencies of antibody responses to the P. vivax circumspor-
ozoite protein have in fact been found to be similar between Fy2
and Fy+ groups. Nevetheless, responses against erythrocytic
antigens were significantly less frequent among Fy2 individuals
than in Fy+ individuals since Fy2 individuals do not develop
erythrocytic infections [31,32].
Naturally acquired antibody and T cell responses play a major
role in reducing the risk of infection and in clinical protection
against malaria infection [33,34,35]. Blood stage infections in
rodent malaria and in human P. falciparum infections have been
reported to suppress T cell responses against liver stage antigens
[36,37,38,39]. However, suppression of blood stage infections can
permit development of immune responses against liver stage
parasites, as shown by the discovery of two promising P. falciparum
liver stage antigens using sera from people exposed to P. falciparum
malaria while under chloroquine prophylaxis that eliminated
blood stage parasites [15,40,41]. All these data support the notion
that a lower parasite load in the blood may be associated with
increased acquired immunity against reinfection and clinical
protection.
The development of vaccine(s) and other novel interventions
targeted at the control of parasites, especially in this case P. vivax,
requires a better understanding of naturally-acquired immune
response. In previous studies, the cellular and humoral immune
responses against vivax antigens among Fy+ donors had been
compared to those of Fy2 donors [31,32]. However, the Fy+
phenotype is conferred by 5 different genotypes, and the diversity
of immune responses to P. vivax exposure in humans with different
genotypes has not yet been assessed. Since the degree of DARC
expression varies remarkably across different FY genotypes [17],
we hypothesized that the acquisition of humoral immunity against
the blood stage parasites will also vary with the level of DARC
expression. This would be in concurrence with the observation
that susceptibility and resistance to the infection varies between
specific genotypes [42,43]. Furthermore, functional interaction of
the different alleles of DARC with DBP for erythrocytic invasion,
and the different signaling characteristics of the different DARC
alleles after they have bound the DBP, may also be associated with
the load of P. vivax parasites in the blood. Finally, as a chemokine
receptor, DARC may also be involved in the immumodulation of
innate and acquired immune responses against vivax infection. We
therefore embarked on the evaluation of the antibody responses
associated with different DARC genotypes.
Results
DARC is required for the blood stage infection of vivax malaria
and its level of expression varies with specific genotypes associated
with susceptibility and resistance to P. vivax erythrocyte infection
[42,44,45]. This led us to hypothesize that the acquired antibody
responses may also vary with the level of DARC expression. This
project is an attempt to increase our knowledge of natural
acquired immunity against erythrocytic parasites associated with
differential DARC gene expression.
First, we demonstrated differences in the antibody responses to
erythroctyic antigens between the Fy+ and Fy2 groups. We then
demonstrated the potential association of antibody resposnes with
different levels of DARC expression [(A/A or A/B).(A/Bnull or
B/B or B/Bnull)] among Fy+ groups. Finally, we wanted to know
if the differential antibody responses were associated with not only
stratified DARC expression but also with specific DARC
genotypes, since it has been reported that susceptibility to
erythrocytic vivax infection was different between FY*A and
FY*B genotypes [44]. Therefore, we compared the antibody
responses between homozygous and heterozygous FYA or FYB
genotypes. As controls, we carried out similar evaluations with P.
falciparum sporozoite and blood stage antigens, which do not
require interaction with DARC. The circumsporozoite protein
(CSP) was selected as the representative antigen for the pre-
erythrocytic stage as it is the immunodominant surface antigen on
the sporozoite [46] and also the most advanced vaccine candidates
for both vivax and falciparum malaria [47,48]. Merozoite surface
protein 1 (MSP1) was also selected as the representative antigen
for the erythrocytic stage because of the its expression on the
surface of merozoites that invade new red blood cells [49] and its
prominence in both vivax and falciparum vaccine development
[50,51]. The P. vivax Duffy Binding Protein (PvDBP) was identified
as the parasite protein that engages DARC present on the surface
of red blood cells [52,53] and is also being developed as a vaccine
candidate [12].
Distribution of Duffy genotypes
In Colombia and throughout the South American continent,
the majority of the clinical cases of malaria are caused by P. vivax
(,70%), while P. falciparum is responsible for the remaining ,30%
[54,55]. We recruited 233 donors from the malaria-endemic
regions of Apartardo and Turbo along the Caribbean coast of
Colombia (Table 1). All donors who participated in this study had
been living in the endemic areas for at least 5 years and had not
experienced symptomatic malaria in the previous 12 months.
About a quarter of the subjects (26%, n=60) were Duffy negative
(FY*Bnull/FY*Bnull). Among the Duffy positive individuals, the
heterozygous FY*A/FY*B genotype was the most common
Acquired Antibodies to Vivax
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other genotypes in the study population (FY*A/FY*A, FY*A/
FY*Bnull, FY*B/FY*B and FY*B/FY*Bnull) were 9, 13, 15, and
15%, respectively (Table 1). The overall prevalence of FY*A and
FY*B alleles expressed as homozygous or heterozygous among the
entire study population was 44% and 65% respectively. We also
recruited 30 donors from Medellin, a non-malaria endemic city in
Colombia. These included 5 Fy2 (17%) and 25 Fy+ (83%)
individuals. Their blood samples were used to standardize the
assay protocols and as unexposed controls.
Broad antibody responses against P. vivax and
P. falciparum malaria were induced by natural exposure
We assessed antigen-specific antibody responses by ELISA to
each of 3 P. vivax and 2 P. falciparum antigens in sera from each of
the individual donors among different DARC genotypes. There
were no detectible anti-malaria antibodies in any of the 30 non-
exposed control donors living in the non-endemic area (data not
shown). The frequency of antibody responses to parasite antigens
among donors living in the malaria endemic areas of Apartado
and Turbo is presented in Figure 1. One hundred thirty-nine
donors (60%) had antibodies against at least one of the five P. vivax
or P. falciparum antigens that were tested. Thirty-seven donors
(16%) had antibodies against at least one P. vivax and one P.
falciparum antigen (Figure 1A). The majority of these (84%,
n=31) were Duffy positive (Fy+) individuals.
A total of 114 donors (49%) had antibodies against at least one
of the P. vivax antigens assessed (Figure 1B). Among these, 28
donors (12%) had antibodies against both P. vivax sporozoite
[circumsporozoite protein (PvCSP)] and erythrocytic antigens
[merozoite surface protein 1 (PvMSP1) or Duffy binding protein
(PvDBP)]. Fifty-six donors had antibody against PvCSP. However,
only 4 Individuals had antibodies against all 3 P. vivax antigens
tested (PvCSP, PvMSP1 and PvDBP), while 4 had antibodies
against two erythrocytic antigens (PvMSP1 and PvDBP) but not to
the sporozoite antigen PvCSP (Figure 1B).
Antibody responses to P. falciparum antigens are presented in
Figure 1C. Sixty-four (64) donors (27%) had antibodies against at
least one of the two P. falciparum antigens tested and 5 donors (2%)
had antibodies against both PfCSP and PfMSP1.
Table 1. Frequencies of genotypes for Duffy antigen receptor for chemokines (DARC) under the study.
Endemic areas,
Colombia Genotype frequencies of Duffy positive FY+ Total FY+ Total FY2
FY*A/*A FY*A/*B FY*A/*Bnull FY*B/*B FY*B/*Bnull FY*Bnull/*Bnull
Turbo (N=155) 13 (8.4)
a 26 (16.8) 23 (14.8) 17 (11.0) 24 (15.5) 103 (66.5) 52 (33.5)
Apartado (N=78) 8 (10.3) 26 (33.3) 7 (9.0) 17 (21.8) 12 (15.4) 70 (89.7) 8 (10.3)
Total (N=233) 21 (9.0) 52 (22.3) 30 (12.9) 34 (14.6) 36 (15.5) 173 (74.2) 60 (25.8)
aNumber (%) of individuals expressing the genotype(s).
doi:10.1371/journal.pone.0011437.t001
Figure 1. Broad antibody responses against malaria were induced by natural exposures in Colombia. We assessed malaria antigen-
specific antibody responses in 233 donors living in Caribbean coast town (Apartado and Turbo) of Colombia. One hundred thirty nine (60%) donors
had antibodies against at least one of five malaria antigens examined. Numbers represent the responders who had antibodies against both P. vivax
and/or P. falciparum antigens (A), different P. vivax antigens, PvCSP, PvMSP1, PvDBP (B), or different P. falciparum antigens PfCSP and PfMSP1 (C).
doi:10.1371/journal.pone.0011437.g001
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are presented as the average Index of Reactivity (IR). The IR is
calculated as the average OD value of each sample at 450 nm
divided by the sum of average OD values of negative controls (US
donors) and 3 standard deviations. Using this standardized IR
calculation, none of the 30 donors from the non-malaria endemic
area had detectable antibodies to any of the 5 malaria antigens
(data not shown). Among the responders from the malaria
endemic responders, the average IR for PvCSP, PvMSP1 and
PvDBP were 0.83, 0.82, and 0.64, respectively. Those for PfCSP
and PfMSP1 were 0.62 and 0.93, respectively (Table 2).
Antibodies against P. vivax pre-erythrocytic antigen are
comparable among Fy2 and Fy+ donors
About a third of the donors living in malaria-endemic regions of
Apartado and Turbo had significant antibodies against PvCSP
(n=80, 34%). The majority of those that had PvCSP antibodies
were Fy+ (n=60, 75%) and the remaining were Fy2 (n=20,
25%). The frequency of responses was however comparable
between Fy+ and Fy2 (35% and 33%, p=0.85) (Table 2). The
magnitude of responses measured by IR was also similar between
Fy+ and Fy2 populations (0.88 and 0.79 respectively, p=0.2996)
(Figure 2A).
Antibodies against P. vivax erythrocytic antigens differ
between Duffy positive and Duffy negative donors
A total of 49 donors (25%) living in the malaria-endemic areas
had significant antibodies against PvMSP1. The majority of those
with PvMSP1 antibodies (90%) were Fy+ (n=44). The frequency
of the responses was significantly higher in Fy+ (16%) than in Fy2
(8%) donors (p=0.005) (Table 2). The magnitude of the responses
(IR distribution) was also significantly different between Fy+ and
Fy2 donors (p=0.014) (Figure 2B). Furthermore, of the 185
samples from malaria-endemic regions assessed, only 17 (9%) had
antibodies against PvDBP and all were Fy+ donors (17 out of 147
tested, 12%). No Fy2 donor from malaria-endemic regions had
antibodies against PvDBP. Therefore, both the frequency and
magnitude of the responses against PvDBP were significantly
different between Fy+ and Fy2 donors (p=0.001 for frequency
and p=0.0396 for IR, respectively) (Table 2 and Figure 2C).
In contrast, the frequencies and magnitudes of antibodies
against both P. falciparum sporozoite antigen (PfCSP) and
erythrocytic antigens (PfMSP1) were comparable among Fy+
and Fy2 donors. Only 14% (n=33) of donors living in malaria-
endemic areas had antibodies against PfCSP. There were no
significant differences in terms of the frequencies (p=0.308) and
magnitude (p=0.1694) of the responses between Fy+ and Fy2
donors (Table 2 and Figure 2D). Among 36 donors (15%) who
had antibodies against PfMSP1, there was also no difference in the
frequencies (p=0.175) and magnitude (p=0.5265) of the responses
(Table 2 and Figure 2E).
Frequency and magnitude of antibodies against P. vivax
erythrocytic antigens in Duffy positive donors varies with
FY genotypes
Among the specific Fy+ genotypes, the frequencies of responses
against PvCSP among those with double positive alleles (FY*A/
FY*B and FY*B/FY*B) were low compared to their correspond-
ing single negative allele genotypes (FY*A/FY*Bnull, FY*B/
FY*Bnull). 37% and 26% compared to 43% and 42%, respectively
(Table 2). However, the differences were not statistically
significant (Table 2, Figure 3A).
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invasion. We compared the antibodies to blood stage antigens
with the stratified DARC expression based on (FY*A/FY*A or
FY*A/FY*B).(FY*A/FY*Bnull, FY*B/FY*Bnull, or FY*B/
FY*B) [29]. The antibody responses to PvMSP1 were detected
in sera from 16 out of 73 in the high DARC expression group
(FY*A/FY*A and FY*A/FY*B) compared to 28 out of 100 in the
low DARC expression group (FY*A/FY*Bnull, FY*B/FY*Bnull,
or FY*B/FY*B). The difference was not significant between the
two groups (p=0.364). However, there were significant differences
in the prevalence of antibodies to PvDBP between the high and
the low DARC expression groups (3/73 vs. 14/100, respectively)
(p=0.031). This may be the first hint that high DARC expression
may be associated with low antibody responses to vivax blood
stage antigens.
We next wanted to determine which specific genotypes of
DARC may be responsible for antibody responses. For PvMSP1,
the frequency of the responses was much higher in FY*B/
FY*Bnull (12/36, 33%) than in FY*B/FY*B (3/34, 9%)
(p=0.012) individuals (Table 2). In addition, the magnitude of
the responses was also significantly greater in FY*B/FY*Bnull
(IR=1.0860.58) than in FY*B/FY*B (IR=0.5760.43)
(p=0.0447) (Table 2 and Figure 3B). A similar low trend in
the responses to PvMSP1 was also observed in FY*A/FY*B
compared to that in FY*A/FY*Bnull (25% and 43%, respectively).
However, the differences in terms of frequency (p=0.086) and
magnitude (p=0.3664) of the responses in this paired group were
not significant (Table 2 and Figure 3B).
For PvDBP, the frequencies of the responses were found
obviously higher among those with a single negative FY allele
(22% for FY*A/FY*Bnull and 27% for FY*B/FY*Bnull) than in
those with corresponding double positive FY alleles (4% for
FY*A/FY*B and 6% for FY*B/FY*B) with p=0.025 and 0.022,
respectively (Table 2). However, the magnitudes of the responses
are different only between FY*B/FY*B (IR=0.5560.21) and
FY*B/FY*Bnull (IR=1.0460.84) (p=0.0047) (Table 2), but not
between FY*A/FY*B and FY*A/FY*Bnull (p=0.098)
(Figure 3C).
However, with P. falciparum sporozoite (PfCSP) and erythrocytic
antigens (PfMSP1), no such trend was observed among the specific
Fy+ genotypes (Table 2). The frequencies of the responses against
PfCSP in FY*A/FY*B and FY*A/FY*Bnull donors were 21% and
14%, respectively, while those in FY*B/FY*B and FY*B/
FY*Bnull were 12% and 11%, respectively (Table 2). There
were also no significant differences in the magnitudes of the
responses in these paired groups measured by IR distribution
(p=0.8446 and 0.4961, respectively) (Figure 3D). For PfMSP1,
the frequencies of recognition by FY*A/FY*B and FY*A/
FY*Bnull were 19% and 23% respectively, while those for
FY*B/FY*B and FY*B/FY*Bnull were 15% and 11%, respec-
tively (Table 2). The IR distribution was also similar between
both groups (p=0.5335 and 0.3092, respectively) (Figure 3E).
Figure 2. Antibody responses against P. vivax erythrocytic antigens are significantly greater in Fy+ than in Fy2 individuals. Immune
recognition of P. vivax sporozoite antigen (A: PvCSP) and blood stage antigens (B: PvMSP1, C: PvDBP), or P. falciparum sporozoite antigen (D: PfCSP)
and blood stage antigen (E: PfMSP1) by sera of Fy+) and Fy2 donors were assessed by ELISA. Values are expressed as Index of Reactivity (IR) that is
calculated as test OD divided by cut-off OD. The cut-off OD is the average OD value of US donors (with no prior exposure to malaria)+3 SD.
doi:10.1371/journal.pone.0011437.g002
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erythrocytic antigens
To search for which subtype(s) of immunoglobulin (Ig) may be
responsible for the antibody responses to erythrocytic antigens, we
analyzed the IgM and IgG subclasses within 29 Fy+ donors who
had high magnitudes of total IgG antibodies against PvMSP1 (17
donors) and/or PvDBP (12 donors) (Figure 4). One hundred
percent of donors tested had IgM to PvMSP1, whereas, only 23%
of the donors who had IgG to PvDBP had detectable IgM to
PvDBP. The difference in frequencies of IgM responses to
PvMSP1 versus PvDBP is significant (p,0.0004) (Figure 4A).
The majority of Fy+ donors that responded to PvMSP1 had IgG1
(95%). The frequencies of other IgG subclasses to PvMSP1 were at
similar levels (IgG2 at 68%, IgG3 at 53%, and IgG4 at 63%,
respectively). The dominant subclass IgG to PvDBP was IgG1
(92%), then IgG3 (85%), IgG2 (77%), and IgG4 (46%),
respectively (Figure 4A). The magnitude of IgG1
(IR=11.963.37) was also dominating the responses to PvMSP1,
and then IgG3 (IR=2.9661.07), IgG2 (IR=1.4760.15), and
IgG4 (IR=1.4560.27), respectively (Figure 4B). The magnitude
of IgG1 to PvDBP was significantly lower than that to PvMSP1
(IR at 4.3 versus 11.9, p,0.0011). However, there were no
statistically significant differences in terms of the magnitudes of
other IgG subclasses between PvDBP and PvMSP1 (Figure 4B).
We further compared the frequencies of the IgG subclasses to
PvMSP1 and PvDBP among the different FY genotypes.
Significant differences were detected in the frequencies of IgG3
responses to PvMSP1 between FY*A/FY*B and FY*A/FY*Bnull
(p=0.015), and of IgG1 to PvDBP between FY*B/FY*B and
FY*B/FY*Bnull (p=0.035). There was no additional pattern
observed for other IgG subclasses to PvMSP1 and PvDBP
(Figure 4C).
Discussion
The lack of DARC among almost all individuals of West
African origin has been suggested to be due to natural selection
induced by P. vivax [56,57]. This idea, however, is controversial
and P. vivax has been observed in some populations lacking
DARC, indicating that the parasite may be able to use other host
cell receptors for invasion if DARC is not present [28,58,59].
The presence or absence of DARC has been associated with
resistance and susceptibility to a range of infectious and non-
infectious diseases [13,14,22,23,24,25]. Individuals that lack
DARC (Duffy negative, Fy2) are known to be ‘resistant’ to P.
Figure 3. The levels of antibody responses against P. vivax erythrocytic antigens differ among different Duffy genotypes. Immune
recognition of P. vivax sporozoite antigen (A: PvCSP) and blood stage antigens (B: PvMSP1, C: PvDBP), or P. falciparum sporozoite antigen (D: PfCSP)
and blood stage antigen (E: PfMSP1) by sera of donors with different Duffy genotypes FY*A/FY*B (A/B), FY*A/FY*Bnull (A/Bnull), FY*B/FY*B (B/B) and
FY*B/FY*Bnull (B/Bnull). Values are expressed as Index of Reactivity (IR) that is calculated as test OD divided by cut-off OD. The cut-off OD is the
average OD value of US donors (with no prior exposure to malaria)+3 SD. The IR of donors with FY*A/FY*B genotype is compared with those of FY*A/
FY*Bnull, and FY*B/FY*B with FY*B/FY*Bnull using Student’s t-test and p values,0.05 were considered significant.
doi:10.1371/journal.pone.0011437.g003
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susceptible to the sporozoite-induced liver stage infection for
which DARC is not required. Our earlier study and those of
others revealed that humoral and cellular immune responses to P.
vivax pre-erythrocytic antigens such as CSP are present in Fy2
individuals [31,32]. Among Fy+ individuals, however, the
influence of each allele on the acquisition of immune response
against vivax antigens has yet to be fully explored.
The expression levels of erythroid-specific DARC varied with
erythrocyte age and between different FY+ genotypes [43,60,61].
DARC expression was 2-fold higher in FY*A/FY*A homozygotes
than in FY*A/FY*Anull heterozygotes among people living in
Papua New Guinea, and higher DARC expression was associated
with the higher prevalence of P. vivax infection seen in FY*A/
FY*A compared to FY*A/FY*Anull subjects [43]. This was
caused by the significant reduction of the adherence of Duffy
binding protein to the erythrocyte in individuals who carried the
FY*A/FY*Anull allele [60]. Individuals with the FY*B/FY*B
genotype had a higher risk of P. vivax infection than those with
FY*B/FY*Bnull genotype in malaria-endemic regions of Brazil
[44]. Moreover, DARC expression has been found to be lower in
the FY*B/FY*B than in FY*A/FY*A and FY*A/FY*B genotypes
[61]. Hence, apart from the different levels of FY expression, the
specific qualities and subsequent functions of the DARC upon
binding to the vivax Duffy binding protein and post invasion of
erythrocytes, as well as its role in innate immunity as a receptor for
chemokines may all contribute to the resistance and susceptibility
to vivax infection. We were motivated to investigate the influence
of different Duffy positive alleles on the acquisition of anti-P. vivax
immunity among individuals living in malaria-endemic regions.
First, we demonstrated that broad antibody responses were
detected by ELISA to both P. vivax and P. falciparum in individuals
living in the two malaria endemic areas in Colombia that we
studied (Figure 1). The higher prevalence of recognition of at
least one P. vivax antigen (44%, n=103) compared to recognition
of the corresponding P. falciparum antigen(s) (27%, n=64) probably
reflects the higher level of P. vivax transmission in these areas
compared to that of P. falciparum [62,63]. However, the overall low
prevalence of recognition of the individual antigens reflects the
relatively low level of malaria transmission in these areas and the
fact that our selection criteria excluded individuals with active
infections.
The high level of recognition of PvCSP regardless of the
presence or absence of DARC had previously been recorded
among individuals living on the Pacific coast of Colombia [32] and
in Brazil [64]. There was no significant difference in the frequency
of antibodies to the sporozoite and liver-stage antigen PvCSP
among Fy+ and Fy2 individuals (p=0.2996). Since sporozoites do
not use DARC to infect hepatocytes, Fy+ and Fy2 individuals
should be equally susceptible to sporozoite infection [65,66].
To determine whether the acquired antibody responses
associated with ‘‘natural’’ protection, we focused our studies on
Figure 4. P. vivax erythrocytic antigen specific IgM and IgG subclass profiles among different Duffy genotypes. IgM and IgG subclass
among Fy+ donors that had total IgG against PvMSP1 and PvDBP was measured by ELISA to determine the frequencies (A) and magnitude (B) of
responses against PvMSP1 and PvDBP. IgM and IgG subclass against PvMSP1 and PvDBP were also compared among donors with different Duffy
genotypes (C). Samples are considered positive when the OD reading is . average OD of naı ¨ve controls + 3SD for frequency of responses or index of
reactivity (IR) is greater than 1 for the magnitude of responses, respectively.
doi:10.1371/journal.pone.0011437.g004
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had undetectable parasitemia by blood smear at the time of
enrollment and no history of malaria symptoms in the past 12
months. Long-lasting antibodies and memory B cell responses in
other low malaria transmission endemic areas have also been
reported to be associated with naturally acquired protection [35].
As we show in Table 2, the antibody responses to PvMSP1
differed significantly between Fy+ and Fy2 individuals in both
frequency (p=0.005) and magnitude (p=0.014) (Figure 2B). This
observation is consistent with the requirement for DARC for P.
vivax erythrocytic infection [31,32]. We suspect that the very few
Fy2 donors in the current study that did have detectable anti-
PvMSP1 antibodies had been transiently exposed to PvMSP1 after
the release of merozoites from infected hepatocytes into the blood.
These merozoites would have been cleared rapidly from the
circulation because they would be unable to invade the Fy2
erythrocytes in these individuals.
The major finding in this study was within the Fy+ group
(Table 2 and Figure 2–3), in which the frequencies and
magnitudes of the antibody responses to P. vivax erythrocytic
antigens were significantly higher in individuals possessing a single
negative allele (FY*A/FY*Bnull and FY*B/FY*Bnull) than in
double positives (FY*A/FY*B and FY*B/FY*B). This is exactly
opposite of the expected level of DARC expression [43,61] and
susceptibility to P. vivax infection [42,67]. It is known that the
elevated DARC expression in double-positive individuals confers a
higher risk of P. vivax infection in comparison to those with one
negative gene (FY*A/FY*Bnull, FY*B/FY*Bnull) [43,44,60,61].
Furthermore, active erythrocytic malaria infections have been
reported to induce immune suppression that prevents the host
from mounting an effective immune response against the blood
stage parasites and other co-infecting agents
[38,68,69,70,71,72,73]. This immune suppression ranges from
inhibition of dendritic cell maturation [38], to inhibition of the
generation of specific CD4 T cells [69] and apoptosis of specific
CD4 T cells [73]. Thus, it is likely that the high susceptibility to P.
vivax blood stage infection and concomitant high P. vivax
erythrocytic parasite load in FY*A/FY*B and FY*B/FY*B
double-positive individuals may contribute to the suppression of
antibody responses against erythrocytic antigens when compared
with FY*A/FY*Bnull and FY*B/FY*Bnull individuals. The
higher antibody levels observed in those with a single negative
FY allele may also limit parasite load during subsequent infections
that may in turn reduce or prevent the immune suppression
induced by erythrocytic parasites. Finally, based on DARC’s role
as a sink for excess pro-inflammatory cytokines [74], high levels of
DARC expression in FY double-positives may reduce the surplus
of pro-inflammatory cytokines and curb the severity of symptoms;
alternatively, DARC may down-regulate the immune responses
that control the erythrocytic parasitemia.
This difference in immune recognition between FY*A/FY*B
and FY*B/FY*B individuals and FY*A/FY*Bnull and FY*B/
FY*Bnull individuals observed with PvMSP1 was confirmed with
a second P. vivax blood stage antigen, PvDBP, which is involved in
P. vivax erythrocytic invasion. Our observations that the antibody
responses to two P. vivax blood stage antigens are higher in single
positive than in double-positive individuals leads us to speculate
that immune responses to multiple erythrocytic antigens in hosts
with low parasite load could act synergistically against erythrocytic
parasite invasion and development, providing clinical protection
against subsequent reinfection.
In order to determine whether the differential frequencies of
recognition to blood versus sporozoite antigens by FY genotypes
were restricted to P. vivax, we investigated the recognition of PfCSP
and PfMSP1 in the same study population (Table 2, Figures 2
and 3). As expected, no such variation in antibody response
against P. falciparum antigens with FY genotype was observed.
Finally, we wanted to know whether any specific Ig subtypes are
responsible for the naturally acquired antibodies that are
associated with individual DARC genotypes. IgM responses to
malaria are more likely to be detected early after infection and are
expected to switch from the IgM isotype to the cytophilic isotypes
IgG1 and/or IgG3, a switch that has been associated with clinical
control of erythrocytic parasites [75,76]. In some endemic areas
the IgG1 response to PvMSP1 is higher, whereas in other areas the
IgG3 response dominates [77]. In this study, strong IgM and IgG
responses to PvMSP1 were detected in the same Fy+ individuals
(Figure 4), indicating that the IgM response did not compromise
the induction and development of IgG1 and IgG3 responses to this
antigen. The magnitude of IgG1 response to PvMSP1 was 3 times
greater than the IgG1 response to PvDBP. However, the
frequency of IgG3 responses to PvMSP1 was significantly lower
in FY*A/FY*B than in FY*A/FY*Bnull (p=0.015) individuals, as
were the IgG1 responses to PvDBP in FY*B/FY*B compared to
FY*B/FY*Bnull individuals (p=0.035). Therefore, the lower IgG3
and IgG1 components of the total IgG response may account for
the decreased responses to P. vivax erythrocytic antigens in humans
with the double positive FY*A/FY*B and FY*B/FY*B genotypes,
respectively (Figure 4C). However, the immune mechanism by
which differential DARC expression manipulates the specific IgM
and IgG subclass profiles associated with clinical protection need
to be determined.
In summary, we observed that frequency and magnitude of
antibodies specific for P. vivax erythrocytic antigens varied with the
host DARC genotype. Donors with genotypes associated with
higher levels of DARC expression and higher susceptibility to P.
vivax infection were found to have lesser frequencies and lower
magnitudes of specific antibodies against PvMSP1 and PvDBP.
IgG3 and IgG1 may account for the decreased responses to P. vivax
erythrocytic antigens in humans with FY*A/FY*B or FY*B/FY*B
genotypes. This supports the notion that one of the primary
mechanisms by which P. vivax evades host immunity is through
DARC indirectly down-regulating humoral responses against
erythrocytic invasion and development. These results represent
an important advance in our understanding of blood-stage
immunity to P. vivax that will inform the rational design and
development of effective vaccines to control P. vivax malaria.
Materials and Methods
Study populations
Subjects were recruited from two malaria-endemic cities of
Turbo (8u59420N, 76u4491230W) and Apartado (7u529400N,
76u379440W) both of which are on the Caribbean coast of
Colombia, South America. Their inhabitants are mainly a mixture
of indigenous, Hispanic and African backgrounds. Banana
cultivation is the major source of income. They both have high
migration rates, and malaria transmission is perennial and
unstable, with a mean of 10 infectious bites per 1,000 people.
During the 2004 to 2008 period, the means of annual P. vivax
infectious bites are 323 in Turbo and 84 in Apartado per 1,000
inhabitants. P. falciparum is less frequent in these two cities during
the same period (mean annual infectious bites: Turbo=44,
Apartado=11) (personal communication with local health au-
thorities) [62,63,78]. The causes of malaria infections in these two
areas are comparable; 72% vivax, 28% falciparum and only
0.11% with mixed infection. All the subjects were above 18 years
old and were voluntarily recruited. The purpose of the study was
Acquired Antibodies to Vivax
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to participate in the study. Only subjects who had long been
residing in the study area for more than 5 years and have no
symptoms of malaria within the past year were enlisted. Subjects
included in the study were only those with no detectable P. vivax or
P. falciparum parasites in blood smears on the day of sample
collection. A total of 233 subjects were enrolled from malaria-
endemic areas of Turbo (n=155) and Apartado (n=78) (Table 1).
For malaria infection naı ¨ve controls with specific DARC
genotypes, 30 subjects were recruited from Medellin, where there
is no malaria transmission. Additional eight adult US donors who
had no previous history of malaria or trip to malaria-endemic
region were also used as ELISA assay control. Whole blood
samples were obtained for Duffy genotyping and the separated
sera were used for anti-malaria antibody screening. The study
protocol and consent forms were approved by the Ethics
committee for research in humans of Sede de Investigacion
Universitaria (CBEIH-SIU), Universidad de Antioquia (Medellı ´n,
Colombia) and Western Institute Review Board (WIRB), USA.
Duffy genotyping
Genomic DNAs from the peripheral blood of all donors were
purified using the QIAamp kit (Qiagen), and the quality was
assessed in 1.5% agarose gel. PCR was performed to amplify
1000 bp using the following primers: P1, 59CCTTTT-
TCCTGAGTGTAGT39 (sense) and P2, 59GCAGAGCTGC-
CAGCGGAAGA39 (antisense) as described previously (68). The
PCR conditions were: 95uC 4 min, 35 cycles of 1 min at 94uC,
1 min at 58uC, and 1 min at 58uC, and final 10 min at 72uC.
PCR products were purified using Qiagen kit (Valencia, CA) for
sequence analysis. Primers P1, P2, or P38 (59AGGCTTGTG-
CAGGCAGTG39) (68) were used for sequencing reactions. A
single nucleotide substitution (T46C) at the promoter region
abolishes the expression of the DARC in erythroid tissues (Fy
2,
genotype FY*Bnull/FY*Bnull, phenotype Fya
2b
2). A single
nucleotide substitution (G131A) at the exon region of DARC
determines the allele specificity among Duffy positive donors (Fy
+).
Recombinant antigens
The recombinant P. vivax circumsporozoite protein (PvCSP)
that includes the amino terminus repeat region (3X repeat 1 and
3X repeat 2), and carboxyl terminus was provided by Dr. KL Sim
(Protein Potential LIc, MD). Recombinant P. vivax MSP1
corresponding to MSP1 P. falciparum merozoite surface protein 1
(PfMSP119) and P. falciparum MSP1 were obtained from MR4, VA.
Recombinant P. vivax Duffy Binding Protein (PvDBP) correspond-
ing to region II of the protein was kindly provided by J.H Adams
(University of South Florida, Tampa, FL) and P. falciparum CSP
long synthetic peptide (LSP) corresponding to the amino acid 282–
383 of the C-terminal region was obtained from Dr. G. Corradin
(University of Lausanne, Switzerland) [79].
Evaluation of antibody responses
Enzyme Linked ImmunoSorbent Assay (ELISA) was performed
in 96 well flat-bottom-plates (Nunc-Immuno Module, USA). Wells
were coated with recombinant proteins PvCSP, PvMSP1 or
PfMSP1 at 2.5 mg/mL (PvDBP at 2 mg/mL, PfCSP LSP at 1 mg/
mL) in 50 ml of PBS buffer (pH 7.4) and incubated overnight at
4
0C. The plates were washed with 200 ml of wash buffer
(0.05%Tween-20 in PBS) using Bio-TEK Washer (ELx405) and
then blocked with 200 ml of blocking buffer (5% nonfat dry milk in
PBS) for 1 hour at room temperature (RT). Fifty microliters (50ml)
of 1:50 serum dilutions were added to the coated wells and then
incubated for 2 hours at room temperature. After another
washing, 50 ml of HRP-labeled goat anti-human IgG (H+L) at
1:4000 in 2.5% milk PBS-Tween-20 was added and the plates
were kept at room temperature for 1 hour. For assessment of IgM
and IgG1-4 subtypes, the HRP-labeled mouse anti-human
antibodies were used at 1:1000 following the manufacturer’s
instruction (Southern Biotech, Birmingham, AL, USA). They were
later developed with tetramethylbenzidine (TMB) substrate
(Sigma-Aldrich) and the OD was measured at 450 nm with
ELISA Autoreader MR5000 (Dynatech, Chantilly, CA). All the
assays were performed in triplicates and repeated twice. The
antibody recognition by individual sera is expressed as Index of
Reactivity (IR) that is test OD reading divided by cut-off OD. The
cut-off OD is calculated as the average OD reading of negative
control donors (US donors with no prior exposure to malaria)+3
standard deviations. A sample is considered positive when the IR
value is $1.
Statistical analysis
Statistical analyses were performed using Graphpad prism 5.
Differences in the means were assessed using Student’s t-test and
Chi-squired test. P values ,0.05 were considered significant.
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